CLINICAL IMPLICATION OF ??+ T CELL RECOVERY AFTER ??+ T CELL DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH HEMATOLOGIC MALIGNANCY
(Abstract release date: 05/21/15)
EHA Library. JinSeo J. 06/12/15; 102711; PB2029
Jong JinSeo
Contributions
Contributions
Abstract
Abstract: PB2029
Type: Publication Only
Background
Human γ + T cells exhibit an ability to kill tumors but do not recognize major histocompatibility complex, thus have shown limited risk of graft-versus-host disease (GVHD).
Aims
The purpose of this study were to determine antitumor efficacy of γ + T cells in children with hematologic malignancy after αβ+ T cell depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
Methods
Ten children (6 males, 4 females, median age 12.3 years) with hematologic malignancy received haplo-HSCT after ex vivo depletion of αβ+ T cells between May 2012 and December 2013 at AMCCH. Of 10 patients, 1 had ETP-ALL in CR2 who relapsed after MSD-HCT, 1had MLL in relapse after 2 rounds of URD-HCT, 5 had AML [2 CR1, 2 CR2, 1 non-remission (NR)], 2 had JMML (1 CR1, 1 NR), and 2 had NHL (1 CR2 and 1 CR3) who relapsed after AUTO-HCT. The median number of CD34+, αβ+, γ + and CD3+ cells infused was 10.6 x 106/Kg, 6.3 x 105/Kg, 2.1 x 107/Kg and 22.9 x 106/Kg, respectively. Proportion of TCR γ + T cells in T lymphocyte were analyzed by using Gallios flow cytometer™ (Beckman Coulter, Fullerton, CA, USA) after HSCT.
Results
All 10 patients engrafted and 1 patient experienced grade IV acute GVHD without treatment related mortality. At a median follow-up period of 387 days (range, 208 - 766), 5 patients (1 ETP-ALL, 1 MLL, 2 AML, 1 NHL) relapsed at the median 131 days (range, 42-234) after haplo-HSCT. The median dose of infused γδ+ T cell for 5 patients without relapse and 5 with relapse were 2.2 x 107/Kg and 1.8 x 107/Kg. The median proportion of γ + T cells after HSCT was higher in non-relapsed patients than in relapsed patients. ( 69.4% vs 29.3% at 1 month, 44.2% vs 6.2% at 2 months and 36.8% vs 9.1% at 3 months post-transplant) At a median follow-up of 12 months probability of 1 year relapse-free survival was 48.0%, and probability of 1 year overall survival was 78.8%.
Summary
These findings suggest a correlation between an increase in the proportion of γ + T cells and improved relapse-free survival after αβ+ T cell depleted haplo-HSCT. However, further studies including prospective large numbered trial are needed to confirm our results.
Keyword(s): Haploidentical stem cell transplantation, Immune reconstitution, T cell depletion
Session topic: Publication Only
Type: Publication Only
Background
Human γ + T cells exhibit an ability to kill tumors but do not recognize major histocompatibility complex, thus have shown limited risk of graft-versus-host disease (GVHD).
Aims
The purpose of this study were to determine antitumor efficacy of γ + T cells in children with hematologic malignancy after αβ+ T cell depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
Methods
Ten children (6 males, 4 females, median age 12.3 years) with hematologic malignancy received haplo-HSCT after ex vivo depletion of αβ+ T cells between May 2012 and December 2013 at AMCCH. Of 10 patients, 1 had ETP-ALL in CR2 who relapsed after MSD-HCT, 1had MLL in relapse after 2 rounds of URD-HCT, 5 had AML [2 CR1, 2 CR2, 1 non-remission (NR)], 2 had JMML (1 CR1, 1 NR), and 2 had NHL (1 CR2 and 1 CR3) who relapsed after AUTO-HCT. The median number of CD34+, αβ+, γ + and CD3+ cells infused was 10.6 x 106/Kg, 6.3 x 105/Kg, 2.1 x 107/Kg and 22.9 x 106/Kg, respectively. Proportion of TCR γ + T cells in T lymphocyte were analyzed by using Gallios flow cytometer™ (Beckman Coulter, Fullerton, CA, USA) after HSCT.
Results
All 10 patients engrafted and 1 patient experienced grade IV acute GVHD without treatment related mortality. At a median follow-up period of 387 days (range, 208 - 766), 5 patients (1 ETP-ALL, 1 MLL, 2 AML, 1 NHL) relapsed at the median 131 days (range, 42-234) after haplo-HSCT. The median dose of infused γδ+ T cell for 5 patients without relapse and 5 with relapse were 2.2 x 107/Kg and 1.8 x 107/Kg. The median proportion of γ + T cells after HSCT was higher in non-relapsed patients than in relapsed patients. ( 69.4% vs 29.3% at 1 month, 44.2% vs 6.2% at 2 months and 36.8% vs 9.1% at 3 months post-transplant) At a median follow-up of 12 months probability of 1 year relapse-free survival was 48.0%, and probability of 1 year overall survival was 78.8%.
Summary
These findings suggest a correlation between an increase in the proportion of γ + T cells and improved relapse-free survival after αβ+ T cell depleted haplo-HSCT. However, further studies including prospective large numbered trial are needed to confirm our results.
Keyword(s): Haploidentical stem cell transplantation, Immune reconstitution, T cell depletion
Session topic: Publication Only
Abstract: PB2029
Type: Publication Only
Background
Human γ + T cells exhibit an ability to kill tumors but do not recognize major histocompatibility complex, thus have shown limited risk of graft-versus-host disease (GVHD).
Aims
The purpose of this study were to determine antitumor efficacy of γ + T cells in children with hematologic malignancy after αβ+ T cell depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
Methods
Ten children (6 males, 4 females, median age 12.3 years) with hematologic malignancy received haplo-HSCT after ex vivo depletion of αβ+ T cells between May 2012 and December 2013 at AMCCH. Of 10 patients, 1 had ETP-ALL in CR2 who relapsed after MSD-HCT, 1had MLL in relapse after 2 rounds of URD-HCT, 5 had AML [2 CR1, 2 CR2, 1 non-remission (NR)], 2 had JMML (1 CR1, 1 NR), and 2 had NHL (1 CR2 and 1 CR3) who relapsed after AUTO-HCT. The median number of CD34+, αβ+, γ + and CD3+ cells infused was 10.6 x 106/Kg, 6.3 x 105/Kg, 2.1 x 107/Kg and 22.9 x 106/Kg, respectively. Proportion of TCR γ + T cells in T lymphocyte were analyzed by using Gallios flow cytometer™ (Beckman Coulter, Fullerton, CA, USA) after HSCT.
Results
All 10 patients engrafted and 1 patient experienced grade IV acute GVHD without treatment related mortality. At a median follow-up period of 387 days (range, 208 - 766), 5 patients (1 ETP-ALL, 1 MLL, 2 AML, 1 NHL) relapsed at the median 131 days (range, 42-234) after haplo-HSCT. The median dose of infused γδ+ T cell for 5 patients without relapse and 5 with relapse were 2.2 x 107/Kg and 1.8 x 107/Kg. The median proportion of γ + T cells after HSCT was higher in non-relapsed patients than in relapsed patients. ( 69.4% vs 29.3% at 1 month, 44.2% vs 6.2% at 2 months and 36.8% vs 9.1% at 3 months post-transplant) At a median follow-up of 12 months probability of 1 year relapse-free survival was 48.0%, and probability of 1 year overall survival was 78.8%.
Summary
These findings suggest a correlation between an increase in the proportion of γ + T cells and improved relapse-free survival after αβ+ T cell depleted haplo-HSCT. However, further studies including prospective large numbered trial are needed to confirm our results.
Keyword(s): Haploidentical stem cell transplantation, Immune reconstitution, T cell depletion
Session topic: Publication Only
Type: Publication Only
Background
Human γ + T cells exhibit an ability to kill tumors but do not recognize major histocompatibility complex, thus have shown limited risk of graft-versus-host disease (GVHD).
Aims
The purpose of this study were to determine antitumor efficacy of γ + T cells in children with hematologic malignancy after αβ+ T cell depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
Methods
Ten children (6 males, 4 females, median age 12.3 years) with hematologic malignancy received haplo-HSCT after ex vivo depletion of αβ+ T cells between May 2012 and December 2013 at AMCCH. Of 10 patients, 1 had ETP-ALL in CR2 who relapsed after MSD-HCT, 1had MLL in relapse after 2 rounds of URD-HCT, 5 had AML [2 CR1, 2 CR2, 1 non-remission (NR)], 2 had JMML (1 CR1, 1 NR), and 2 had NHL (1 CR2 and 1 CR3) who relapsed after AUTO-HCT. The median number of CD34+, αβ+, γ + and CD3+ cells infused was 10.6 x 106/Kg, 6.3 x 105/Kg, 2.1 x 107/Kg and 22.9 x 106/Kg, respectively. Proportion of TCR γ + T cells in T lymphocyte were analyzed by using Gallios flow cytometer™ (Beckman Coulter, Fullerton, CA, USA) after HSCT.
Results
All 10 patients engrafted and 1 patient experienced grade IV acute GVHD without treatment related mortality. At a median follow-up period of 387 days (range, 208 - 766), 5 patients (1 ETP-ALL, 1 MLL, 2 AML, 1 NHL) relapsed at the median 131 days (range, 42-234) after haplo-HSCT. The median dose of infused γδ+ T cell for 5 patients without relapse and 5 with relapse were 2.2 x 107/Kg and 1.8 x 107/Kg. The median proportion of γ + T cells after HSCT was higher in non-relapsed patients than in relapsed patients. ( 69.4% vs 29.3% at 1 month, 44.2% vs 6.2% at 2 months and 36.8% vs 9.1% at 3 months post-transplant) At a median follow-up of 12 months probability of 1 year relapse-free survival was 48.0%, and probability of 1 year overall survival was 78.8%.
Summary
These findings suggest a correlation between an increase in the proportion of γ + T cells and improved relapse-free survival after αβ+ T cell depleted haplo-HSCT. However, further studies including prospective large numbered trial are needed to confirm our results.
Keyword(s): Haploidentical stem cell transplantation, Immune reconstitution, T cell depletion
Session topic: Publication Only
{{ help_message }}
{{filter}}